Company: BDRX
Filing Date: 2025-01-21
Form Type: 424B3
Source: 0001214659-25-000936
Chunk: 10

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-21
Form: 424B3
Chunk 10
---
 U.S. federal or state law for the relief of debtors.

(j) “” means any day on which (i) the Principal Market is open for trading, including any day on which the Principal Market is
open for trading for a period of time less than the customary time, and (ii) any day except any Saturday, any Sunday, any day which is
a federal legal holiday in the United Kingdom or any day on which banking institutions in London, England are authorized or required by
law or other governmental action to close.

| -2- |

(k) “” means, for any security as of any date, the last closing sale price on such date for such security on the Principal
Market as reported by the Principal Market (to be appropriately adjusted for any reorganization, recapitalization, non-cash dividend,
share split, reverse share split, Depositary Share-Ordinary Share ratio change or other similar transaction).

(l) “” means the United Kingdom Companies Act 2006.

(m) “” means any information disclosed by either party to the other party, either directly or indirectly, in writing,
orally or by inspection of tangible objects (including, without limitation, documents, prototypes, samples, plant and equipment), which
is designated as “Confidential,” “Proprietary” or some similar designation. Information communicated orally shall
be considered Confidential Information if such information is confirmed in writing as being Confidential Information within ten (10) Business
Days after the initial disclosure. Confidential Information may also include information disclosed to a disclosing party by third parties.
Confidential Information shall not, however, include any information which (i) was publicly known and made generally available in the
public domain prior to the time of disclosure by the disclosing party; (ii) becomes publicly known and made generally available after
disclosure by the disclosing party to the receiving party through no action or inaction of the receiving party; (iii) is already in the
possession of the receiving party without confidential restriction at the time of disclosure by the disclosing party as shown by the receiving
party’s files and records immediately prior to the time of disclosure; (iv) is obtained by the receiving party from a third party
without a breach of such third party’s obligations of confidentiality; (v) is independently developed by the receiving party without
use of or reference to the disclosing party’s Confidential Information, as shown by documents and other competent evidence in the
receiving party’s possession; or (vi) is required by law to be